Background. It is known that more than 80 % of children with chronic pyelonephritis (СP) have abnormal intestinal disorders, which requires correction and recovery of microflora by inclusion of probiotics into therapeutic and prophylactic regimens. The purpose of the study was to study the effectiveness of probiotic Subalin in the comprehensive treatment of СP in preschool children. Materials and methods. We examined 40 children aged 0 to 6 years with a primary СP and preserved kidney function. Group I of patients received standard therapy according to the protocol. Bifido- or lactobacilli were used to correct the dysbiosis in children of this group. Patients of group II received basic therapy in combination with probiotic Subalin according to the scheme suggested by us. The rate of elimination of intoxication and dyspeptic syndromes, duration of clinical and laboratory remission of the underlying disease were assessed. Results. Evaluation of clinical effectiveness of Subalin in children for 1 month showed its more significant effectiveness in eliminating the main manifestations of dysbiosis. A significantly more pronounced frequency of normalization of feces was revealed on the background and after treatment with Subalin, in contrast to the comparison group. There was a tendency to decrease in duration (p ≤ 0.1) and a significant (p < 0.05) decrease in manifestations of intoxication syndrome in children of group II. During the 6 months of follow-up, 94.7 % of the children in group II had a significantly higher antiretroviral effectiveness of the therapy, and the duration of complete clinical and laboratory remission was 5.9 ± 0.4 months, compared with the identical indices in group I (66.7 % and 3.1 ± 0.1 months, respectively). Conclusions. The obtained results confirmed the expediency of using Subalin in the comprehensive treatment of CP in children of preschool age.

Slobodyan I. The content of serum interleukin in children with chronic pyelonephritis: association with disease duration, frequency and activity of exacerbations. Tavricheskij mediko-biologicheskij vestnik. 2013;16(3) Par 3 (63);130-4. (In Russian).

Lukyanenko NS, Kens KA, Petritsa NA. Possibilities of the early diagnosis of nephrosclerosis in children up to 3 years in the period of complete remission of acute uncomplicated pyelonephritis. Zdorov'ye Rebenka. 2016;7(75):106-10. (In Ukrainian). doi: 10.22141/2224-0551.7.75.2016.86734.

Harshman VP, Kryuchko TO, Kolenko IO, Kushnereva TV, Tkachenko OY. Role of genetic mutations in development of immunological and clinical disorders in children with chronic pyelonephritis. Wiadomości Lekarskie. 2017;LXX(1):47-51. PMID: 28343193.

Gonchar MA, Senatorova MA, Muratov GR, et al. Clinical observation and strategy of management of chronic renal insufficiency in a child with congenital determinate renal pathology. Sovremennaya Pediatriya. 2016;5(77):107-11, (In Russian). doi: 10.15574/SP.2016.77.107.

Lavrenchuk OV, Driyanska VE, Bagdasarova IV, et al. Anti-recurrent therapy of chronic urinary infections in children. Sovremennaya Pediatriya. 2013;4(52):157-61.

Szajewska H, Canani RB, Guarino A. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Journal of Pediatric Gastroenterology and Nutrition. 2016;62(3):495-506. doi: 10.1097/MPG.0000000000001081.

Ilke Beyitler,and Salih Kavukcu Probiotics for Prophylaxis and Treatment of Urinary Tract Infections in Children. Article in Iranian Journal of Pediatrics In Press(In Press). 2016 Oct. doi: 10.5812/ijp.7695.

Chapman CM, Gibson GR, Rowland I. Effects of single- and multi-strain probiotics on biofilm formation and in vitro adhesion to bladder cells by urinary tract pathogens. Anaerobe. 2014;71-6. doi: 10.1016/j.anaerobe.2014.02.001. Epub 2014 Feb 25.

Claudia Vuotto, Francesca Longo and Gianfranco Donelli. Probiotics to counteract biofilm-associated infections: promising and conflicting data. International Journal of Oral Science. 2014;6:189-94. doi: 10.1038%2Fijos.2014.52.

Varsha Moudgal, editor; Alpa Garg, Nitesh Upadhyay, contributors. Infectious Diseases. Volume 15, Part 6: Probiotics: A Review. pp. 1-13. Available from: www.turner-white.com

Psakhis IB, Makovskaya TYe. Modern Possibilities and Prospects for the Using Probiotics from the Group of Self-Eliminating Antagonists in the Treatment of Infectious Diseases. Zdorov'ye Rebenka. 2014;4(55):132-6. (In Russian). doi: 10.22141/2224-0551.4.55.2014.76176.

Marushko YuV, Hrachova MH, Marushko YeYu. Properties of B.subtilis and their use in clinical practice. Zdorov'ye Rebenka. 2015;2(61):23-6. (In Ukrainian). doi: 10.22141/2224-0551.2.61.2015.75105.

Pro zatverdzhennja protokolіv nadannja medichnoї dopomogi dіtjam za specіal'nіstju “Ditjacha nefrologіja”: protokol lіkuvannja dіtej z іnfekcіjami sechovoї sistemi і tubuloіntersticіal'nim nefritom. Nakaz MOZ Ukraїni No 627 [About approval of the protocols for medical care for children on specialty ‘Pediatric Nephrlogy’: protocol of treatment of children with urinary tract infections and tubulointerstitial nephritis. The order of MoH N 627 dated 03.11.08]. Available from: http://www.moz.gov.ua/ua/portal/dn_20081103_627.html

Marie Lefevre, Silvia M. Racedo, Gabrielle Ripert, et al. Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Ageing. 2015;12:24. doi: 10.1186%2Fs12979-015-0051-y.

http://www.uroweb.org

Izmailova OV, Shlykova OA, Bobrova NO, Kaidashev IP. Relationship between the TLR2 and TLR4 gene polymorphisms with a predisposition to certain urogenital infections. Cytology and Genetics. 2011 Jul-Aug;45(4):29-35. doi: 10.3103/S0095452711040050.

Maidannyk VG. Probiotics: Prospects for use in children. Mezhdunarodnyj zhurnal pediatrii, akusherstva i ginekologii. 2013;4(3):62-80.

Kryuchko TO, Nesina IM, Tkachenko OYa. Diagnostic algorithm and peculiarities of monitoring for infants with disorders of the gastrointestinal tract. Wiadomości Lekarskie. 2017;LXX(2):275-81.